CVRx Analyst Price Targets - Benzinga

CVRx Inc

CVRXNASDAQ

Trade with Public

Trade with Public

$1.42

-0.035-2.41%

Dern. MÀJ: Oct 27, 6:05 AM

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

CVRx Analyst Price Targets - Benzinga

CVRx Analyst Price Targets

Wall Street analyst price targets and consensus rating for CVRx (CVRX).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

5Buy

1Hold

1Sell

Consensus RatingOverweight# Analysts7Avg. Consensus PT$10Upside to Avg. PT+610.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	Cantor Fitzgerald	Sarah James	PT Cut	Overweight	$13→$5
Aug 7, 2026	Lake Street	Frank Takkinen	Downgrade	Buy→Hold	$14→$4
Apr 14, 2026	Canaccord Genuity	William Plovanic	Maintained	Buy	$10
Feb 13, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$11→$10
Nov 6, 2025	Canaccord Genuity	William Plovanic	PT Raise	Buy	$9→$11
Nov 6, 2025	Cantor Fitzgerald	Ross Osborn	PT Raise	Overweight	$11→$13
Aug 5, 2025	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$11
May 9, 2025	Piper Sandler	Matt O'Brien	PT Cut	Overweight	$20→$12
May 9, 2025	JP Morgan	Robbie Marcus	Downgrade	Neutral→Underweight	$15→$7
Apr 8, 2025	Lake Street	Frank Takkinen	PT Cut	Buy	$19→$14
Apr 8, 2025	Canaccord Genuity	William Plovanic	PT Cut	Buy	$23→$18
Feb 5, 2025	JP Morgan	Robbie Marcus	PT Raise	Neutral	$13→$15
Feb 5, 2025	Piper Sandler	Matt O'Brien	PT Raise	Overweight	$16→$20
Feb 5, 2025	Canaccord Genuity	William Plovanic	PT Raise	Buy	$22→$23
Jan 17, 2025	Craig-Hallum	Alexander Nowak	PT Raise	Buy	$20→$22
Jan 14, 2025	William Blair	Margaret Kaczor	Upgrade	Market Perform→Outperform	—
Dec 9, 2024	Canaccord Genuity	William Plovanic	PT Raise	Buy	$17→$22
Nov 4, 2024	Craig-Hallum	Alexander Nowak	PT Raise	Buy	$15→$20
Oct 30, 2024	Lake Street	Frank Takkinen	PT Raise	Buy	$12→$15
Oct 30, 2024	Canaccord Genuity	William Plovanic	PT Raise	Buy	$15→$17

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Overweight on CVRx, Lowers Price Target to $5

Cantor Fitzgerald analyst Sarah James maintains CVRx (NASDAQ:CVRX) with a Overweight and lowers the price target from $13 to $5.

Benzinga Newsdesk

PRO
Lake Street Downgrades CVRx to Hold, Lowers Price Target to $3.5

Lake Street analyst Frank Takkinen downgrades CVRx (NASDAQ:CVRX) from Buy to Hold and lowers the price target from $14 to $3.5.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on CVRx, Lowers Price Target to $10

Canaccord Genuity analyst William Plovanic maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $11 to $10.

Benzinga Newsdesk

CVRx Kicks Off One Of The Largest Heart Device Trials In History

CVRx, Inc. initiates landmark BENEFIT-HF trial with FDA-approved Barostim device, aiming to expand heart failure patient population.

Vandana Singh

PRO
Canaccord Genuity Maintains Buy on CVRx, Raises Price Target to $11

Canaccord Genuity analyst William Plovanic maintains CVRx (NASDAQ:CVRX) with a Buy and raises the price target from $9 to $11.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on CVRx, Raises Price Target to $13

Cantor Fitzgerald analyst Ross Osborn maintains CVRx (NASDAQ:CVRX) with a Overweight and raises the price target from $11 to $13.

Benzinga Newsdesk